Innoviva (INVA) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Specialty therapeutics business performance

• Specialty therapeutics generated over $200 million in revenue in the last four quarters, with $37 million in U.S. sales in Q2 and annual growth rates of 40%-50% over recent years.

• Key growth drivers are XACDURO and GIAPREZA, with XACDURO focusing on new account penetration and GIAPREZA on generating additional data for broader use.

• XACDURO faces little competition, addressing carbapenem-resistant Acinetobacter, while GIAPREZA aims to expand its addressable patient population.

• Ex-U.S. markets, especially China and Latin America, are significant, with partnerships like Zai Lab and Dr. Reddy's Laboratories expanding reach.

• Ex-U.S. revenue is recognized through royalties, milestones, and inventory supply, with growth expected to mimic U.S. trends.

Product pipeline and catalysts

• Upcoming launches include zoliflodacin, a novel oral treatment for gonorrhea, addressing rising resistance and offering an alternative to injectable therapies.

• Commercial execution, new medical evidence generation, and expanding ex-U.S. access are key catalysts for future growth.

• Business development and potential new product acquisitions are expected to drive long-term value.

Royalty streams and financial outlook

• Royalty streams from COPD products are highly resilient, with over two-thirds of sales from ex-U.S. markets, buffering against U.S. pricing pressures.

• Expected to generate over $1 billion in royalty revenue over the next five years, supporting ongoing investments and business development.

• Strategic options for monetizing royalty streams are considered, but predictable cash flow is valued for supporting growth.